Wednesday, February 19, 2020

Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi Headquarters in Shanghai

We are excited to share with you that Dr. Peter Schultz, CEO of The Scripps Research Institute, visited our headquarters on October 17 and gave an inspiring public lecture.  Dr. Schultz...

WuXi Wins Prestigious SCRIP Award for “Best Company in the Emerging Market”

We are honored to receive the prestigious distinction from SCRIP Award 2014  in the category of “Best Company in the Emerging Market”, which recognizes the rapid growth, significant accomplishments, and increasing global...

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate...

Congratulations to our partners Ambrx and Zhejiang Medicine Company (ZMC) for completing dose of the first patient for ARX788, a novel antibody-drug conjugate (ADC) product candidate for treating breast cancer and gastric...

WuXi Oncology Receives Award for “Most Valuable Team Player ” from Genentech

We are honored to receive the Award for "Most Valuable Team Player" from Genentech in October 2013, in recognition of the contribution of the Oncology team in accelerating key deliveries with...

WuXi Global Forum 2019

Now in its seventh year, the WuXi Global Forum at the J.P. Morgan Healthcare Conference brings together thousands of leaders onsite and via live broadcasting to promote new thinking on a...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Amicus Therapeutics: A Patient-First Approach to Treating Rare Diseases

Rare diseases have long posed a dual challenge. First, since there are relatively few patients by definition, they are not the highest priority for...